Previous 10 | Next 10 |
Gainers: ACB +26.4% . SCVL +5.8% . PGNX +4.4% . EVLO +3.4% . OPRA +3.4% . More news on: Aurora Cannabis Inc., Shoe Carnival, Inc., Progenics Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Galapagos NV (NASDAQ: GLPG ) and collaboration partner Gilead Sciences (NASDAQ: GILD ) announce results from a Phase 2b/3 clinical trial evaluating filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis (UC). ...
-- Filgotinib 200 mg Demonstrated Greater Efficacy Compared with Placebo in the Induction and Maintenance of Remission in the SELECTION Trial -- -- Rates of Adverse Events Were Low and Comparable Across Treatment Groups -- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (E...
The much-hated bull market is losing steam as optimism about a V-shaped recovery is making room for realism with headlines including 'Why the market could go much lower' and 'The US is risking a second COVID-19 wave'. On the contrary, we still have the Fed pumping unprecedented (my God, I l...
Background This is Part 2 of a 2-part set of articles about Gilead ( GILD ); Part 1 focused on its remdesivir ("RDV") for COVID-19. There is probably more going on at GILD than the focus on RDV in GILD's recent Q1 earnings report and conference call could allow to be discussed. The ...
Image source: The Motley Fool. Galapagos NV (NASDAQ: GLPG) Q1 2020 Earnings Call May 9, 2020 , 11:30 p.m. ET Operator Continue reading
Galapagos NV (GLPG) Q1 2020 Results Conference Call May 8, 2020 8:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - CEO Bart Filius - COO and CFO Piet Wigerinck - Chief Scientific Officer Walid Abi-Saab - Chief Medical Officer Miche...
Galapagos (NASDAQ: GLPG ): Q1 GAAP EPS of -€0.78 beats by €0.03 . More news on: Galapagos NV, Earnings news and commentary, Healthcare stocks news, Read more ...
Lately, interest for Gilead ( GILD ) stock has risen dramatically as a consequence of a potential launch of its COVID-19 drug named Remdesivir. I have been a long-term believer in this company. My investment thesis, also discussed in my December article , is based on three factors: its new ma...
Gilead Sciences (NASDAQ: GILD) has been making waves of late. The company's antiviral drug, remdesivir, is currently perceived as the most promising potential treatment for COVID-19. As a result, Gilead's shares are up by 22% year to date, while the S&P 500 is down by 15% since the beg...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...